Osteoporosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• RANKL 1
• PI3K 0
• NRF2 0
• AKT 0
• CTNNB1 0
• MAPK 0
• SIRT1 0
• mTOR 0
• AMPK 0
• PPAR 0
• STAT3 0
• ERK 0
• NLRP3 0
• YAP 0
• GPX4 0
• GLP-1 1
• TP53 0
• STING 0
• TNF 0
• HIF-1 0
• JAK 0
• METTL3 0
• IL-6 0
• PTEN 0
• VEGF 0
• CXCR4 0
• JNK 0
• MMP-9 0
• ESR1 0
• IL-4 0
• MEK 0
• PINK1 0
• SGLT2 0
• APP 0
• COX-2 0
• CSF1R 0
• DPP-4 0
• FTO 0
• HMGB1 0
• IL-1 0
• KIT 1
• APOE 0
• CD40 0
• CGRP 0
• EGFR 0
• EZH2 0
• FOXP3 0
• MYC 0
• TFEB 0
• ACE2 0
• AXL 0
• BRAF 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CCR5 0
• CDK4/6 0
• FGFR 0
• G6PD 0
• HSP90 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Extending Female Reproductive Longevity: Neurovascular Control of the Ovarian Reserve (dOvary)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting Effective Plant Phosphopeptide–Calcium Formulations Using Machine Learning for Ca/Vitamin D3 and K2 Supplement Development via Pickering Emulsion (CaVita-Phos)

  Christian-Albrechts-Universitaet Zu Kiel· Kiel, Germany· EU contribution €202,125· until Sept 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Human Muscle-Bone Organoid-on-Chip to Study Bone Mechano- Adaptation via Optogenetic Control (BONE-TUNE)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Hypothalamic cell changes during menopause: the neuroendocrine origin of its metabolic alterations (HypoPause)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spain· EU contribution €1,498,325· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  EVOLUTIONARY MECHANISMS OF AGE-RELATED BONE LOSS ACROSS THE HUMAN AND HOMINID SKELETON (STAND UP)

  Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev· Munchen, Germany· EU contribution €401,232· until Dec 2028· 3 countries

5 of 26 running projects, newest first. Listed amounts together: €61.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• DPP4-Inhibitors and Bone Metabolism in Diabetes

  NCT06770894· Azienda Policlinico Umberto I· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 1
• Mendelian Randomization Analysis 90
• CRISPR-Cas Systems 1
• Gene Expression Profiling 60
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 23
• Metabolomics 25
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 3
• Magnetic Resonance Imaging 73
• Machine Learning 79
• Deep Learning 38
• Cohort Studies 236
• Genome-Wide Association Study 83

• A population-based cohort study of fracture risk among 122 255 adults before and after cancer diagnosis compared with matched controls.

  J Bone Miner Res, Oct 2026

• Comparative Effectiveness of Individual Angiotensin Receptor Blockers on Osteoporosis and Osteoporotic Fracture Risk: A Nationwide Active-Comparator New-User Cohort Study.

  Calcif Tissue Int, Oct 2026

• Mortality and healthcare utilization after proximal humeral fractures in patients aged 65 years and older: a register-based cohort study.

  Eur J Orthop Surg Traumatol, Oct 2026

• Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care.

  Support Care Cancer, Oct 2026

• Medication-related osteonecrosis of the jaw in cancer and osteoporosis patients: a retrospective seven-year single-center Norwegian cohort study of clinical profiles and documented soft tissue healing.

  Acta Odontol Scand, Oct 2026

• Sex-specific multimorbidity clusters and all-cause mortality among community-dwelling older adults: findings from the ASPREE cohort.

  J Gerontol A Biol Sci Med Sci, Oct 2026

• High genetic predisposition and vertebral fracture burden in pregnancy and lactation-associated osteoporosis: clinical insights from a Taiwanese cohort.

  Front Endocrinol (Lausanne), Oct 2026

• Anti-osteoporosis medications in persons with and without Parkinson disease in Finland.

  Arch Osteoporos, Oct 2026

• Sex differences in the clinical presentation and complications of primary hyperparathyroidism: insights from a single-center cohort study.

  Endocrine, Sept 2026

• Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan.

  Calcif Tissue Int, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.